Fundraising Fox
Montréal · Seed–Late Stage · 9 people tracked
Find your way into CTI Life Sciences Fund L.P.
Sign up to see every warm intro you have to CTI Life Sciences Fund L.P.
- Paths you didn't know you had: your email and LinkedIn already hold routes to the CTI Life Sciences Fund L.P. team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
Canadian life sciences VC co-created with a major pension fund, acting as a semi-institutional anchor that catalyzes hundreds of millions in follow-on capital despite modest ~$245M fund size.
Source: firm website, verified Aug 3, 2026.
Team · 9 people
from public directories
What they invest in
from 20 of 45 portfolio companiesBiotech ×20Healthtech ×9Medical Devices ×7AI & Machine Learning ×4Deep Tech ×4Digital Health ×3Longevity ×2
HQs:United States×5Canada×3Spain×1
Investments · 45 tracked
founders shown can be your intro pathBy year:2026 · 12017 · 12016 · 12014 · 25 dated
Zymeworks is a biotechnology company that develops novel therapeutics for patients with difficult-to-treat diseases using its proprietary drug-development platforms and in-house R&D.
BiotechHealthtechVancouver, US
ALI TEHRANI(Executive Officer, Director)inGORDON NG(Executive Officer)NEIL KLOMPAS(Executive Officer)inSURJIT DIXIT(Executive Officer)inDAVID TUCKER(Executive Officer)Paul Moore(Chief Scientific Officer)in
Board seatShermaine Tilley· per SEC Form D
Co-investorsBrace PharmaHBM Healthcare InvestmentsLumira VenturesNextech InvestWUTIF CapitalAmplitude Venture Capital
Profound Medical develops real-time MRI-guided thermal ultrasound systems for incision-free ablation of abnormal or cancerous tissue.
BiotechDeep TechHealthtechMedical DevicesMississauga
Arun Menawat(CEO and Chairman of the Board)inRashed Dewan(Executive Officer)inMathieu Burtnyk(Chief Operating Officer)inTom Tamberrino(Chief Commercial Officer)
BoardJean-Francois Pariseau(Director)Damian Lamb(Director)
Co-investorsFACIT (Fight Against Cancer Innovation Trust)Genesys Capital
Vaxcyte is a biotech company developing vaccines to treat or prevent serious infectious diseases.
BiotechDeep TechHealthtechSouth San Francisco, US
Grant Pickering(Chief Executive Officer, Director and Co-Founder)Jeff Fairman(Vice President of Research and Co-Founder)Ashish Khanna(Executive Officer)
BoardTracy Saxton(Director)William Newell(Director)Kurt von Emster(Director)in
Co-investorsAbingworthForesite CapitalFrazier Life SciencesJanus Henderson InvestorsLongitude CapitalMedicxi+4 more
Vaxcyte develops broad-spectrum vaccines to prevent bacterial infections, using a cell-free protein synthesis platform and synthetic chemistry techniques.
BiotechHealthtech
Grant Pickering(Founder)in
Co-investorsBioRock VenturesForesite CapitalFrazier Life SciencesLongitude CapitalPivotal Life SciencesRA Capital+3 more
Thryv Therapeutics is a clinical-stage biotechnology company developing selective inhibitors of serum glucocorticoid inducible kinase 1 (SGK1) for inherited cardiac arrhythmias such as Long QT Syndrome and acquired cardiometabolic diseases.
BiotechHealthtechMedical Devices
Paul F. Truex(Chairman of the Board & Chief Executive Officer)inDebra OdinkinAmy Sehnertin
Co-investorsAmzak HealthadMare BioInnovationsAlexandriaLumira Ventures
Oligon Therapeutics develops RNA-based multi-targeting drugs using its SeekR platform, which combines RNA aptamer oligo-binders with siRNA silencers into a single self-delivering molecule for precise targeting of specific cell types, including T-cells and cancer cells.
AI & Machine LearningBiotech
Spyro Mousses(Founder)in
Co-investorsFonds de solidarité FTQ
Thryv Therapeutics is a clinical-stage biotech developing precision-medicine treatments for genetic arrhythmia syndromes and acquired cardiometabolic diseases using selective inhibitors of serum glucocorticoid inducible kinase 1 (SGK1).
BiotechDigital HealthMedical Devices
Paul F. Truex(Chairman of the Board & Chief Executive Officer)inDebra Odink(President & Chief Development Officer)inAmy Sehnert(Chief Medical Officer)inMatt Killeen(Chief Business Officer)in
BoardSaumya Das(Chief Scientific Advisor)
Co-investorsLumira VenturesadMare BioInnovationsAmzak HealthFonds de solidarité FTQ
AbilityPharma develops innovative oncology therapies that induce autophagy to treat various cancers and address unmet medical needs.
BiotechDigital HealthHealthtechMedical DevicesGirona, ES
Carles Domenech(Founder)in
Co-investorsCapital CellInveready Technology Investment Group
Aeovian Pharmaceuticals is a clinical-stage biopharmaceutical company developing selective small molecule inhibitors to treat rare genetic and age-related diseases caused by dysregulated cellular metabolism.
BiotechBerkeley, US
Allison J. Hulme(CEO & President)inJohn Kincaid(Chief Scientific Officer)inDavis Ryman(Executive Officer)inMicah Zajic(Executive Officer)inIan Massey(Executive Officer)Stelios Tzannis(Executive Officer, Director)
Co-investorsCoastCapFJ LabsLuma GroupSofinnova VenturesvenBio PartnersApollo Health Ventures+1 more
Developing therapeutic peptides targeting rare endocrine diseases (past investment).
Co-investorsAndera PartnersATEM Capital FundEQT Life SciencesKurma PartnersOctalfaSofinnova Partners+4 more
Apollo is a venture capital firm that invests in life-science and biotechnology startups, combining entrepreneurial expertise with deep scientific knowledge to support early-stage companies in drug development and personalized medicine.
BiotechDeep TechHealthtechLongevity
Nils Regge(Co-Founder & General Partner)in
Co-investorsBLN CapitalCoastCapFJ LabsKfW CapitalQuery CapitalTruVenturo GmbH+4 more
Domain Therapeutics is a clinical-stage biopharmaceutical company developing GPCR-targeting therapies to address unmet medical needs in immuno-oncology and inflammation.
BiotechDigital Health
Co-investors3B Future Health FundadMare BioInnovationsOmnes CapitalPanacea VentureSeventure Partners
enGene is a genetic medicine company developing drug therapies across oncology, urology, and other therapeutic areas, with a focus on patient outcomes.
BiotechMedical Devices
Co-investorsLumira Ventures
Epitopea develops off-the-shelf cancer vaccines targeting aberrantly expressed tumor-specific antigens using its proprietary CryptoMap platform.
AI & Machine LearningBiotechHealthtechMontreal, CA
Claude PerreaultPierre Thibault
Co-investorsAdvent Life SciencesCambridge Innovation CapitaladMare BioInnovationsFonds de solidarité FTQ
Find Therapeutics is a clinical-stage biopharmaceutical company developing therapies to treat demyelinating diseases, particularly multiple sclerosis and related conditions affecting myelin repair.
BiotechLongevityMedical DevicesMontreal, CA
Co-investorsadMare BioInnovations
Glycomine develops therapeutics for rare diseases, many of which currently lack disease-modifying treatment options.
BiotechSan Francisco, US
Agnes Rafalko(Executive Officer, Director)inSteven Axon(Chief Executive Officer)inHicham Alaoui(Chief Scientific Officer)inRose Marino(Chief Medical Officer)inPeter McWilliams(Chief Business Officer)Geoffrey Hird(Chief Technology Officer)in
Co-investorsAdvent Life SciencesAsahi Kasei Corporate Venture CapitalChiesi VenturesMission Bay CapitalMission BiocapitalRemiges Ventures, Inc.+6 more
Phenomic AI is a biotech company developing therapies for solid tumors using a machine-learning-powered transcriptomics platform that analyzes single-cell RNA data to identify drug targets and understand tumor biology.
AI & Machine LearningBiotechDeep TechToronto, CA
Sam Cooper(Co-founder & CTO)inOren Kraus(Co-founder)in
Co-investorsCantos VenturesAV8 VenturesGarage CapitalHemi Ventures, LlcToronto Innovation Acceleration PartnersHike Ventures+2 more
A URL shortcut operated by Google that directs users to official Google products and services.
Co-investorsFirst Bight VenturesSwanlaab Venture FactoryAbstract VenturesGeneral CatalystUnion Square Ventures (USV)Y Combinator
.png)
A biologics center of excellence focused on developing and delivering medicines to patients, operating as a subsidiary within the Otsuka pharmaceutical group.
AI & Machine LearningBiotechHealthtechMedical Devices
Zachary Shriver(President and Chief Executive Officer)Karthik Viswanathan(Vice President, Research)in
Co-investorsCycad Group LLCLux CapitalMRL Ventures Fund
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
CellAegis DevicesAeovianCellaegisCervelo PharmaceuticalsChlorion PharmaDalCorDalcor PharmacheuticalsEnobiaGlypharmaIlkosImvKainovaKainova TherapeuticsMedicagoNeuraxonOligon Rna TherapeuticsPhemiPrecitheraProfoundSomnus TherapeuticsTargegenThryvThryv TherapeuticsVectivBioXageniscXTuit Pharmaceuticals
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 5
4 IPOs · 1 acquisitionsZymeworksNASDAQ: ZYMEProfound MedicalNASDAQ: PROFSUTROVAX, INC.NASDAQ: PCVXVaxcyteNASDAQ: PCVXVISTERRA, INC.acq. by Otsuka
Portfolio news
latest coverage across their companiesProfound Medical · stocktitan.net · Sep 3, 2026
Vaxcyte · manilatimes.net · Aug 27, 2026
Aeovian Pharmaceuticals · finsmes.com · Dec 16, 2025
Oligon · finance.yahoo.com · Sep 23, 2025
Frequently asked questions
- How many investments has CTI Life Sciences Fund L.P. made?
- CTI Life Sciences Fund L.P. has 45 tracked investments, 5 of which have exited, including 1 dated in the last 24 months.
- What stage does CTI Life Sciences Fund L.P. invest at?
- CTI Life Sciences Fund L.P. invests at the Seed, Series A, Series B, Series C, Growth, Late Stage stages.
- What sectors does CTI Life Sciences Fund L.P. focus on?
- CTI Life Sciences Fund L.P. focuses on AI & Machine Learning, Biotech, Healthtech, Medical Devices.
- Where is CTI Life Sciences Fund L.P. located?
- CTI Life Sciences Fund L.P. is headquartered in Montréal, CA.
- Does CTI Life Sciences Fund L.P. lead rounds?
- CTI Life Sciences Fund L.P. typically participates in rounds rather than leading them.
- Who does CTI Life Sciences Fund L.P. co-invest with?
- CTI Life Sciences Fund L.P. most often shares deals with Lumira Ventures, Advent Life Sciences, CoastCap, among 48 tracked co-investors.
Images
Similar investors
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
GV (Google Ventures) is a venture capital firm that has invested in AI and machine learning since its early days, backing more than 100 AI companies across infrastructure, life sciences, and applications.
Menlo Ventures is an early-stage venture capital firm backing transformative technology companies, with a strong current emphasis on artificial intelligence across enterprise, healthcare, and consumer markets.
Norwest is a venture capital and growth equity investment firm that has backed over 700 companies across technology, consumer, and healthcare over its 65-year history.
Ambix is a healthcare-focused investment firm that provides funding, strategy, and hands-on support to companies developing medical tools and devices, biochemistry-based technologies, digital health applications, and other novel healthcare solutions. It invests across all stages and also builds companies itself.